Skip to main content
Clinical Trials/NCT02208921
NCT02208921
Completed
N/A

An Observational, Cross Sectional Study to Assess the Prevalence of Chronic Kidney Disease in Type 2 Diabetes Patients in India

AstraZeneca1 site in 1 country3,000 target enrollmentSeptember 2014
ConditionsDiabetes

Overview

Phase
N/A
Intervention
Not specified
Conditions
Diabetes
Sponsor
AstraZeneca
Enrollment
3000
Locations
1
Primary Endpoint
The proportion of T2DM patients with Chronic Kidney Disease (CKD)
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

This non-interventional, multi-centric, cross-sectional study is aimed to determine the prevalence of Chronic Kidney Disease in Indian patients with Type 2 Diabetes (T2DM). 3000 patients will be enrolled from 30 investigative sites all over the country. Each investigative site will be expected to enrol 100 subjects. All the procedures will be completed in a single day.

Detailed Description

This is an observational, multicenter, cross-sectional study to be conducted at 30 sites in India. Endocrinologist/ Diabetologist from multiple private clinics will evaluate the Type 2 Diabetes patients. The study will be conducted over 9-10 months and will be started after obtaining written approval of Independent Ethics Committee (IEC) and written Informed consent of the patient. . Each investigative site will be expected to enrol 100 subjects. All the procedures will be completed in a single day.

Registry
clinicaltrials.gov
Start Date
September 2014
End Date
May 2015
Last Updated
10 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Known cases of T2DM.
  • Male and female patients aged 18 years and above.
  • Must provide written Informed consent.

Exclusion Criteria

  • Patients with known type-1 diabetes.
  • Patients with any form of acute kidney injury based on investigator's discretion.
  • Patients on maintenance dialysis or known renal transplant patients.
  • Patients who have participated in any interventional study within past 3 months prior to entry in this study.
  • Pregnant women.
  • Patients with symptomatic Urinary Tract Infection (UTI) or with history of hematuria.

Outcomes

Primary Outcomes

The proportion of T2DM patients with Chronic Kidney Disease (CKD)

Time Frame: 1 day

The proportion of T2DM patients with CKD as per GFR (Glomerular Filtration Rate)criteria. GFR below 90 ml/min/1.73 m2 is defined as CKD. we will also classify CKD into various groups as per the KDIGO 2013.

Secondary Outcomes

  • Frequency of T2DM patients in various stages of CKD(1 day)
  • Frequency of T2DM patients with CKD in patients with different duration of T2DM(1 day)
  • Frequency of patients with HbA1C less than 7% in T2DM patients with and without CKD(1 day)

Study Sites (1)

Loading locations...

Similar Trials